Tag: 314K

Intellia CEO Unloads $314K in Stock, Maintains Strong Ownership with Over 1 Million Shares

Intellia Therapeutics, a biotech company focusing on CRISPR-based therapies for rare diseases and oncology, recently disclosed a significant…